Sign In
Buy GNGBY
$20.03
+0.205 (+1.03%)
At Close: Jun 03, 2026
Getinge AB (publ) (GNGBY) Q1 2026 Earnings Call Transcript
09:30am, Tuesday, 21'st Apr 2026
Getinge AB (publ) (GNGBY) Q1 2026 Earnings Call Transcript
Analyzing Danaher (NYSE:DHR) and Getinge (OTCMKTS:GNGBY)
04:32am, Saturday, 28'th Feb 2026
Getinge (OTCMKTS:GNGBY - Get Free Report) and Danaher (NYSE: DHR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strengt
Getinge AB (publ) (GNGBY) Q4 2025 Earnings Call Transcript
01:22pm, Tuesday, 27'th Jan 2026
Getinge AB (publ) (GNGBY) Q4 2025 Earnings Call Transcript
Contrasting AMN Healthcare Services (NYSE:AMN) & Getinge (OTCMKTS:GNGBY)
02:14am, Thursday, 11'th Dec 2025
AMN Healthcare Services (NYSE: AMN - Get Free Report) and Getinge (OTCMKTS:GNGBY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses
Reviewing Getinge (OTCMKTS:GNGBY) & Pediatrix Medical Group (NYSE:MD)
01:46am, Wednesday, 10'th Dec 2025
Pediatrix Medical Group (NYSE: MD - Get Free Report) and Getinge (OTCMKTS:GNGBY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses bas
Getinge AB (publ) (GNGBY) Q3 2025 Earnings Call Transcript
06:34am, Tuesday, 21'st Oct 2025
Getinge AB (publ) (OTCPK:GNGBY) Q3 2025 Earnings Call October 21, 2025 4:00 AM EDT Company Participants Mattias Perjos - CEO, President & Director Agneta Palmer - Chief Financial Officer Conference Ca
Getinge AB (publ) (GNGBF) Q2 2025 Earnings Call Transcript
05:36am, Monday, 21'st Jul 2025
Getinge AB (publ) (OTCPK:GNGBF) Q2 2025 Earnings Conference Call July 18, 2025 4:00 PM ET Company Participants Agneta Palmer - Chief Financial Officer Mattias Perjos - CEO, President & Director Confer
Getinge AB (publ) (GNGBF) Q1 2025 Earnings Call Transcript
12:02pm, Tuesday, 22'nd Apr 2025
Getinge AB (publ) (OTCPK:GNGBF) Q1 2025 Earnings Conference Call April 22, 2025 7:00 AM ET Company Participants Mattias Perjos - President & CEO Agneta Palmer - Chief Financial Officer Conference Call
Getinge AB (GNGBF) Q4 2024 Earnings Call Transcript
09:13am, Tuesday, 28'th Jan 2025
Getinge AB (OTCPK:GNGBF) Q4 2024 Results Conference Call January 28, 2025 4:00 AM ET Company Participants Mattias Perjos - President & CEO Agneta Palmer - CFO Conference Call Participants Rickard Ande
Getinge AB (GNGBF) Q3 2024 Earnings Call Transcript
08:42am, Friday, 18'th Oct 2024
Getinge AB (OTCPK:GNGBF) Q3 2024 Earnings Conference Call October 18, 2024 4:00 AM ET Company Participants Mattias Perjos - President & CEO Agneta Palmer - CFO Conference Call Participants Erik Cassel
Getinge misses Q3 forecasts, weighed by quality and delivery issues
06:34am, Friday, 18'th Oct 2024
Swedish medical equipment maker Getinge missed forecasts for third-quarter profit and sales on Friday despite strong orders, hit by delivery issues and costs of solving prolonged quality problems.
Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript
02:03pm, Thursday, 18'th Jul 2024
Getinge AB (OTCPK:GNGBF) Q2 2024 Earnings Conference Call July 18, 2024 4:00 AM ET Company Participants Mattias Perjos - President and Chief Executive Officer Agneta Palmer - Chief Financial Officer C
Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript
01:02pm, Monday, 22'nd Apr 2024
Getinge AB (OTCPK:GNGBF) Q1 2024 Earnings Conference Call April 22, 2024 7:00 AM ET Company Participants Mattias Perjos - President & CEO Agneta Palmer - CFO Conference Call Participants Erik Cassel -
Getinge AB (publ) (GNGBF) Q3 2023 Earnings Call Transcript
12:10pm, Monday, 23'rd Oct 2023
Getinge AB (publ) (OTCPK:GNGBF) Q3 2023 Earnings Conference Call October 23, 2023 4:00 AM ET Company Participants Mattias Perjos - President and Chief Executive Officer Lars Sandstrom - Chief Financia
Getinge: Turnaround Catalysts To Outperform Healthcare Peers
03:43am, Tuesday, 15'th Aug 2023
Getinge AB is a Swedish healthcare medical tech company with a $5 billion market cap and leading positions in multiple niches within its target markets. The company has faced headwinds in recent years
